TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.20nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 1.80nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.10nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.30nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.60nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.10nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.10nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.10nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.70nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.70nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.80nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.90nMAssay Description:Inhibition of SHP-2 activity by small molecule inhibitors was monitored by a biochemical DiFMUP pseudosubstrate-fluorogenic assay. SHP-2 enzyme at fi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 3.90nMAssay Description:SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal st...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Nikang Therapeutics
US Patent
Nikang Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair